Connect with us

Business Wire

MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research

Published

on


MYMD-1 demonstrated favorable safety and tolerability profile across multiple doses, with no clinically relevant adverse events, supporting advancement of the compound for Sarcopenia and Rheumatoid Arthritis

BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, today announced the publication of results from a Phase 1 study of oral tumor necrosis factor-alpha (TNF-α) inhibitor, MYMD-1® (Isomyosamine), in peer-reviewed journal, Drug Research. The randomized, double-blind, placebo-controlled study, intended to evaluate the safety, tolerability, and pharmacokinetic profile of MYMD-1 in healthy adults, found that single daily doses for 3 days and multiple daily doses for 6 days were safe and well tolerated in healthy subjects. The study used single daily doses of 150 mg, 300 mg, and 450 mg, respectively, and multiple daily doses of 600 mg. There were no new or unexpected safety findings and no clinically relevant or severe adverse events reported.

MYMD-1 is an oral next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based autoimmune diseases are treated. Its ease of oral dosing is a significant differentiator compared to currently available TNF-α inhibitors, all of which require delivery by injection or infusion. MYMD-1 has also been shown to selectively block TNF-α where it is overactivated without preventing it from doing its normal job of responding to routine infection. In addition, it has not been shown to cause serious side effects common with traditional immunosuppressive therapies that treat inflammation.

“As the first TNF-α inhibitor to be dosed orally, publication of these data confirm our belief that MYMD-1 may one day offer a new treatment option for patients not served by currently available therapies,” said Chris Chapman MD, President, Director, and Chief Medical Officer at MyMD Pharmaceuticals. “We look forward to upcoming Phase 2 results in sarcopenia and to advancing our MYMD-1 programs in other autoimmune disorders including rheumatoid arthritis and Hashimoto’s thyroiditis.”

MYMD-1 is currently being evaluated in Phase 2 studies for sarcopenia/frailty, a result of the aging process, with data expected in 4Q 2022. MYMD-1 has the potential to be the first drug approved by FDA for the condition. The company also expects to initiate a clinical program in rheumatoid arthritis (RA), which affects more than 1.3 million Americans.1 Along with the growing aging population, autoimmune diseases like RA are becoming more prevalent. The National Institutes of Health estimates that autoimmune diseases overall may affect as many as 24 million Americans.2

About MYMD-1

MYMD-1, an oral selective inhibitor of tumor necrosis factor-alpha (TNF-α), a driver of chronic inflammation, is being studied to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan. MYMD-1 has shown effectiveness in pre-clinical and clinical studies in regulating the immune system. Unlike other therapies, MYMD-1 has been shown in these studies to selectively block TNF-α when it becomes overactivated in autoimmune diseases and cytokine storms, but not block it from doing its normal job of being a first responder to any routine type of moderate infection.

MYMD-1’s ease of oral dosing is another differentiator compared to currently available TNF-α blockers, all of which require delivery by injection or infusion. No FDA-approved TNF inhibitor has ever been dosed orally. In addition, the drug is not immunosuppressive and has not been shown to cause the serious side effects common with traditional therapies that treat inflammation. Because it can cross the blood brain barrier and gain access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related disorders. Its mechanism of action and efficacy in diseases including multiple sclerosis (MS) and thyroiditis have been studied through collaborations with several academic institutions.

About MyMD Pharmaceuticals

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), is a clinical stage biopharma company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases. MyMD’s lead clinical candidate, MYMD-1®, is an orally available next-generation TNF-alpha inhibitor with the potential to transform the way that TNF-alpha based diseases are treated. MYMD-1®, with its small molecule design, improved safety profile and ability to cross the blood brain barrier, has the promise to provide meaningful therapeutic solutions to patients not served by current TNF-alpha inhibitors and as a potential therapy for CNS-based inflammatory and autoimmune diseases. MYMD-1 has demonstrated the potential to slow the aging process and extend healthy lifespan. The company is evaluating MYMD-1® in Phase 2 studies for sarcopenia/frailty, a result of the aging process, as well as early-stage trials for rheumatoid arthritis (RA), with the potential to expand into other applications. MyMD’s second therapeutic candidate is Supera-CBD, a novel, synthetic, non-toxic cannabidiol (CBD) analog that is 8000 times more potent a CB2 agonist (activator) than plant-based CBD. In addition to its potential role in managing addiction, anxiety, chronic pain and seizures, Supera-CBD has also been shown to have anti-inflammatory effects. For more information, visit www.mymd.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “plan,” “will,” “would” and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the timing of, and MyMD’s ability to, obtain and maintain regulatory approvals for clinical trials of MyMD’s pharmaceutical candidates; the timing and results of MyMD’s planned clinical trials for its pharmaceutical candidates; the amount of funds MyMD requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which MyMD operates; MyMD’s ability to retain and attract senior management and other key employees; MyMD’s ability to quickly and effectively respond to new technological developments; MyMD’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on MyMD’s proprietary rights; and the impact of the ongoing COVID-19 pandemic on MyMD’s results of operations, business plan and the global economy. A discussion of these and other factors with respect to MyMD is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed by MyMD on March 31, 2022, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

1 https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Rheumatoid-Arthritis
2 https://www.niehs.nih.gov/health/topics/conditions/autoimmune/index.cfm

Contacts

Investor:
Robert Schatz

(646) 421-9523

rschatz@mymd.com

Media:
Andrea Cohen

Sam Brown, Inc.

(917) 209 7163

AndreaCohen@sambrown.com

This post was originally published on this site



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business Wire

Global Pet Food Ingredients Market Analysis Report 2022-2027: Shift in Focus Toward Natural and Grain-Free Products & Increasing Trend of Pet Humanization to Drive Demand for Premium Pet Products – ResearchAndMarkets.com

Published

on

By


DUBLIN–(BUSINESS WIRE)–The “Global Pet Food Ingredients Market by Ingredient (Meat & Meat Products, Cereals, Vegetables & Fruits, Fats, Additives), Source (Animal-based, Plant Derivatives, Synthetic), Pet (Dogs, Cats, Fish), Form, and Region – Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.

The global pet food ingredients market is estimated to be valued at USD 32.2 billion in 2022. It is projected to reach USD 44.5 billion by 2027, with a CAGR of 6.7%

The market is gaining momentum as pet food ingredients continue to find increased applications across various pet species such as dogs, cats, fish and other pets such as rabbits, birds and horses. The demand for pet food ingredients is gaining significant traction in the industry, especially due to the rising focus of owners on the health and nutrition of pet animals in recent years.

Additionally, the rising innovation in the pet food ingredients market and technological advancements which are enhancing the efficiency of pet food ingredients have contributed to the growth of the market in recent years.

By ingredient, meat & meat products segment occupies the highest market share during the forecast period

Based on ingredient, meat & meat products accounted for the highest market share among all other segments owing to their rich taste and nutrition profile owing to which they have high acceptability rate among pet animals.

Meat & meat products are also effective in supporting the gut health of pets due to their higher amino acid content which is effective in controlling infections and inhibition of growth of pathogens and bacteria. Due to their high acceptability rate among pets, rich nutrition profile and desirable health benefits, they are highly preferred by pet owners, contributing to their increased demand.

By pet, dog segment is forecasted to account for the dominant segment during the forecasted period

Based on pet, the dog segment accounts for the highest market share. Dogs offer an attractive market for manufacturers of pet food ingredients owing to their varied nutritional requirements, compared to other pet animals.

A significant number of additives such as vitamins, minerals and enzymes are added to dog food products to satisfy their nutritional requirements. Dogs also account among the most preferred pets among owners, having a healthy adoption rate around the world which presents significant business opportunities for manufacturers of pet food ingredients.

By source, animal-based pet food ingredients are expected to retain their position as the dominant segment over the forecast period

Based on source, the animal-based segment is expected to account for the largest and fastest-growing segment over the forecast period because of the increasing demand among pet owners owing to their large health benefits and increased acceptability among pet animals.

They are associated with a range of health benefits such as enhancement of health of skin and coat of pet animals and are also considered effective in the inhibition and growth of pathogen and controlling infections such as bladder stones and urinary tract infections, which contributes to their increased demand in the industry.

By form, the dry segment is expected to retain its position as the dominant segment over the forecast period

Based on form, the dry segment is likely to account for the dominant and the fastest growing segment over the forecasted period.

The dry form of pet food ingredients are associated with a range of desirable characteristics such as having a richer nutritional profile, along with being highly cost-effective as compared to liquid form of pet food ingredients. They also offer higher convenience of handling during processing and storage owing to their lower moisture content which is also likely to drive their demand over the forecasted period.

The North America region accounts for the dominant market share for the pet food ingredients market during the forecast period

North America region is expected to retain its position as the dominant region for pet food ingredients market during the forecasted period.

The region’s large market share is attributed to a variety of reasons such as increase in adoption of pet animals owing to the rising pet humanization trend in the region. The pet owners in the region demonstrate a high level of awareness regarding health and nutrition of their pets, which contributes to the higher demand of pet food ingredients in the region.

The region’s growth has also been bolstered due to the presence of a significant number of major pet food ingredients manufacturing companies. The US, one of the North American countries, also accounts among the leading pet food ingredient producers, and has a large pet population which has also significantly contributed towards the growth of pet food ingredients industry in the region.

Competitive landscape

Key players in this market include BASF SE (Germany), Darling Ingredients Inc. (US), Cargill (US), Ingredion (US), DSM (Netherlands), Omega Protein Corporation (US), ADM (US), Kemin Industries, Inc. (US), Chr. Hansen Holding A/S (Denmark), and Roquette Freres (France).

Premium Insights

  • Increasing Adoption of Pets and Rising Pet Humanization Trend to Propel Growth
  • US and Animal-based Accounted for the Largest Shares in North American Market in 2021
  • Dogs Segment to Dominate During Forecast Period
  • Dry Segment to Dominate During Forecast Period
  • North America to Dominate During Forecast Period
  • Meat & Meat Products to Dominate During Forecast Period

Market Overview

Macroeconomic Factors

  • Rising Pet Adoption Among Urban Population
  • Increasing Trend of Pet Humanization to Drive Demand for Premium Pet Products

Drivers

  • Increase in Pet Expenditure with Substantial Rise in Pet Food Expenditure
  • Switch from Mass Products to Organic Pet Food Ingredients
  • Acceptance of Insect-based Protein and Oils by Pet Owners

Restraints

  • Non-Uniformity of Regulations Hindering International Trade
  • Limited Availability of Ingredients and Price Sensitivity

Opportunities

  • Use of Cannabis in Pet Food
  • Technological Advancements to Enhance Product Development
  • Shift in Focus Toward Natural and Grain-Free Products

Challenges

  • Capital Investment for Equipment
  • Threat from Counterfeit Products

Value Chain

  • Research and Product Development
  • Raw Material Sourcing
  • Production and Processing
  • Distribution
  • Marketing & Sales

Company Profiles

Key Players

  • BASF SE
  • Darling Ingredients Inc.
  • Cargill
  • Ingredion
  • DSM
  • Omega Protein Corporation
  • ADM
  • Kemin Industries, Inc.
  • Chr. Hansen Holding A/S
  • Roquette Freres

Other Players

  • Saria A/S GmbH & Co. KG
  • The Scoular Company
  • Lallemand Inc.
  • Phileo by Lesaffre
  • Labudde Group Inc.
  • Linkone Ingredient Solutions
  • 3D Corporate Solutions
  • Hydrite Chemical
  • Green Source Organics
  • Biorigin
  • Vitiva D.O.O.
  • AFB International
  • Symrise
  • Mowi ASA
  • Zinpro Corp.

For more information about this report visit https://www.researchandmarkets.com/r/8y915n

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

This post was originally published on this site



Source link

Continue Reading

Business Wire

Wedbush Securities’ Senior Vice President, Equity Research, Gerald, Pascarelli, CFA® Initiates Coverage on U.S. Cannabis Names CRLBF, CURLF, GTBIF & TCNNF

Published

on

By


 

LOS ANGELES–(BUSINESS WIRE)–Wedbush Securities, one of the nation’s leading independent diversified financial services providers, is pleased to announce that Equity Research Analyst, Gerald Pascarelli, CFA® is launching coverage in the U.S. Cannabis sector. On the heels of his initiation on 11 stocks in the Non-Alcoholic and Alcoholic Beverages sectors in October 2022, Gerald will expand to cover four stocks within the cannabis space: Cresco Labs Inc. (CRLBF), Curaleaf Holdings, Inc. (CURLF), Green Thumb Industries, Inc. (GTBIF) and Trulieve Cannabis Corp. (TCNNF). This initiation represents an extension into an area that was not covered by Wedbush, further expanding the scope of coverage of the firm’s Equity Research team.


Prior to joining Wedbush, Gerald served as VP of Equity Research at Cowen, Inc., where he covered both the alcoholic and non-alcoholic beverage sectors for eight years and was also an integral part of the firm’s coverage launch into the cannabis sector in 2016. In his previous role, Gerald contributed to several research white papers and cross-category consumer reports, focused on market sizing, consumer demographics and cannabis’ impact on alcoholic beverages. Prior to Cowen, Gerald spent eight years at Kingdon Capital Management, a New York-based hedge fund. He states, “As we near the end of 2022, we believe that brighter days lie ahead for the U.S. cannabis industry. I look forward to developing this new vertical of research here at Wedbush and am compelled by the current risk/reward setup for this sector of the market.”

Kevin Merritt, Wedbush Securities’ Director of Research says, “We are thrilled to have Gerald initiating in the Cannabis space as it heralds a new area of growth for our Equity Research team. As we tap into this never-before-covered space for the firm, Gerald and his team are the perfect fit to champion this new effort.”

Gerald received his Bachelor’s degree in Business Administration with a concentration in Finance from the State University of New York, at Albany. He is also a CFA® charterholder.

About Wedbush Securities

Wedbush Securities is the largest subsidiary of Wedbush Financial Services. Since its founding in 1955, Wedbush has been a leader in the financial services industry, providing our clients, both private and institutional, with a wide range of securities brokerage, wealth management, and investment banking services. Headquartered in Los Angeles, California with 100 registered offices and nearly 900 colleagues, the firm focuses on client service and financial safety, innovation, and the utilization of advanced technology.

Follow Us:

Wedbush Twitter
Wedbush Facebook

Wedbush LinkedIn
Wedbush Instagram

Contacts

Natalie A. Svider

213-688-8057

publicrelations@wedbush.com

This post was originally published on this site





Source link

Continue Reading

Business Wire

WeighPack Introduces High Precision Check Weigher for Tightest Tolerances

Published

on

By


LAS VEGAS–(BUSINESS WIRE)–#automation–WeighPack Systems’ WeightCheQ 0-250 features high precision electromagnetic force restoration (EMFR) weigh cell technology to achieve the highest tolerances possible while reading in three decimal points.


The WeightCheQ 0-250 is engineered with a weight range of 0 – 250 grams and will weigh product accurately and consistently to +/- 0.01 gram. This tight tolerance level makes it the perfect choice for check weighing pharmaceuticals, cosmetics, precious metals, cannabis pre-rolls and more.

This high-performance weigher will automatically reject product that is outside of the user’s set tolerance level and deposit it into a convenient accumulation drawer for reuse. An easy-to-read visual operation interface notifies the user when product is within the targeted weight by illuminating a green light and then changing to a red light when the target weight is out of tolerance.

The 0-250 includes a large color touchscreen, does not require compressed air and easily integrates into existing packaging lines for an immediate improvement in any quality assurance process.

This compact, modular check weigher also features heavy-duty stainless steel frame construction, food-grade belts, upstream and downstream data links, 20-recipe storage and does not require changeover parts to move between product lines.

See video of this system in action at www.weighpack.com/primary-packaging-video-library/.

For product inquiries, visit www.weighpack.com/weighpack-sales-inquiries/.

Paxiom is the national sales, system integration and service provider for the state-of-the-art packaging machine technology manufactured by WeighPack, ValTara and EndFlex. From weighing, filling, bagging and wrapping to cartoning, tray forming, case packing and palletizing, Paxiom has delivered over 7,000 packaging solutions to over 30 countries. Customers can see these solutions in person by visiting an Xperience Center in Las Vegas, Miami, Milwaukee, Montreal, Toronto or Schio, Italy.

Contacts

David Morgan, Director of Marketing, dmorgan@weighpack.com, 702-450-0808 x625

This post was originally published on this site





Source link

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media